沙美特罗替卡松联合罗红霉素对老年支气管扩张患者肺功能和炎症因子的影响  

Effects of Salmeterol Combined with Roxithromycin on Pulmonary Function and Inflammatory Factors in Elderly Patients with Bronchiectasis

作　　者：刘茵[1] 夏敏[1] 孙林[1] 艾伟[1] 周红兵[1] 

机构地区：[1]崇州市人民医院呼吸内科,四川崇州611230

出　　处：《中国药房》2015年第3期305-308,共4页China Pharmacy

摘　　要：目的:观察沙美特罗替卡松联合罗红霉素对老年支气管扩张患者肺功能和炎症因子的影响。方法:将82例老年支气管扩张患者随机均分为观察组和对照组。两组患者均给予适当吸氧、支气管舒张药、祛痰药和止咳药等常规治疗。在此基础上,对照组患者给予罗红霉素分散片0.15 g,口服,每天2次;观察组患者在对照组治疗的基础上给予沙美特罗替卡松粉吸入剂,每天2吸。两组患者疗程均为6个月。观察两组患者治疗前后生活质量评分和呼吸困难评分、肺功能指标[1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1%)、FEV1占用力肺活量比值(FEV1/FVC)]、动脉血气指标{动脉血氧分压[p(O2)]、动脉血二氧化碳分压[p(CO2)]}、炎性因子[白细胞介素(IL)-4、IL-6、IL-10、金属蛋白酶(MMP)-9、超敏C反应蛋白(hs-CRP)]及不良反应发生情况。结果:治疗前两组患者生活质量评分、呼吸困难评分、肺功能指标、动脉血气指标、炎症因子比较,差异均无统计学意义(P>0.05)。治疗后两组患者生活质量评分、呼吸困难评分、p(O2)、IL-4、IL-6、MMP-9、hs-CRP均显著低于同组治疗前,且观察组低于对照组;肺功能指标、p(CO2)、IL-10均显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:沙美特罗替卡松联合罗红霉素可改善老年支气管扩张患者的肺功能,减轻炎症反应,安全性较好。OBJECTIVE： To observe the effects of salmeterol combined with roxithromycin on pulmonary function and inflammatory factors in elderly patients with bronchiectasis. METHODS： 82 elderly patients with bronchiectasis were randomly divided into observation group and control group. Both group received routine treatment as oxygen inhalation, bronchodilators, eliminating phlegm, relieving a cough, etc. Control group was additionally treated with Roxithromyein dispersible tablet 0.15 g orally, twice a day. Observation group was additionally treated with Salmeterol powder inhalant, twice a day, on the basis of control group. The treatment course of 2 groups lasted for 6 months. The quality of life, dyspnea score, pulmonary function indicators [FEV1, FEV1%, FEVI/FVC], blood gas index [p（O2） and p（CO2）], and the level of inflammatory factors [IL-4, IL-6, IL-10, MMP-9, hs-CRP] of 2 groups were compared before and after treatment. RESULTS： Before treatment, the scores of quality of life and dyspnea, lung function indicators, blood gas analysis index, inflammatory factors showed no statistically significant difference between 2 groups （P〉0.05）. After treatment, the scores of quality of life and dyspnea, p（CO2）, the levels of IL-4, IL-6, MMP-9 and hs-CRP in 2 groups were significantly lower than before, and those of observation group were lower than those of control group; lung function indicators, p（O2） and IL-10 were significantly higher than before, and those of observation group were higher than those of control group; there was statistical significance （P〈0.05）. CONCLUSIONS： Salmeterol combined with roxithromycin can improve pulmonary function and relieve inflammatory reaction in elderly patients with bronchiectasis.

关 键 词：沙美特罗替卡松 罗红霉素 支气管扩张 肺功能 炎症因子 

分 类 号：R563[医药卫生—呼吸系统]